Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides…
2 analysts rate GRFS Buy on consensus.
Consensus price target: $10.87 (+43.78% upside from $7.56)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $8.09B | +0.2% | $432.08M |
| 2024 | $8.07B | +9.41% | $175.59M |
| 2023 | $7.38B | +8.71% | $47.35M |
Stock data for GRFS: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics